ORAL ABSTRACT PRESENTATION SESSION

Friday, September 30, 2016

GCOS2016-OA-001

The Impact of Androgen Deprivation on One-year Mortality in a Large Prostate Cancer Registry with Cardiovascular Risk Factors

Presenting Author: Dr. Kristopher Swiger, Vanderbilt University Medical Center, Nashville, TN, USA

GCOS2016-OA-002

Understanding Cardiac Issues in Multiple Myeloma patients: An ongoing Prospective Observation of Cardiac Safety with Proteasome Inhibition (PROTECT) study

Presenting Author: Dr. Trafina Jadhav, Division of Cardiology, Vanderbilt University Medical Center, Nashville, TN, USA

GCOS2016-0A-003

Cardiac symptoms, signs, new cardiac medication and left ventricular ejection fraction (LVEF) changes with 6 versus 12 months adjuvant trastuzumab: 2,500 patients in the Persephone Trial

Presenting Author: Prof. Helena Earl, Department of Oncology, University of Cambridge, Addenbrooke’s Hospital, Cambridge, Cambridgeshire, UK

POSTER PRESENTATION SESSION

Thursday, September 29, 2016

GCOS2016-P1-001

Cardiovascular Events After exposure to Nilotinib in Chronic Myeloid Leukemia: A Single Institution Study, Long term follow up.

Presenting Author: Dr. Nazanin Aghel, Division of Cardiology, University Health Network, University of Toronto, Toronto, ON, Canada

GCOS2016-P1-002

Use of Entresto (sucubitril/valsartan) in Anthracycline Induced Cardiomyopathy

Presenting Author: Maria Anwar, South Health Campus, Alberta Health Services, Calgary, AB, Canada

GCOS2016-P1-003

Incidence and outcomes of chemotherapy-induced cardiomyopathy patients among referrals for advanced heart failure

Presenting Author: Dr. Raquel Araujo-Gutierrez, Houston Methodist Research Institute, Houston, TX, USA

GCOS2016-P1-004

The influence of exercise training on indices of autonomic nervous system function among women undergoing paclitaxel chemotherapy for breast cancer

Presenting Author: Kelcey Bland, Rehabilitation Sciences, University of British Columbia, Vancouver, BC, Canada

GCOS2016-P1-005

Cardiovascular complications of ibrutinib: a systematic review and meta-analysis

Presenting Author: Dr. Francois Caron, Population Health Research Institute, Hamilton, ON, Canada

GCOS2016-P1-006

Chemotherapy Treatment with either Panitumumab or Vinorelbine Increases the Risk of Developing Atrial Fibrillation in Lung Cancer

Presenting Author: Dr. Brandon Chalazan, Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA

GCOS2016-P1-007

Effect of Remote Ischaemic Conditioning in ONCology patients undergoing chemotherapy: Background and study design of the ERIC-ONC study

Presenting Author: Dr. Robin Chung, University College London, Hatter Cardiovascular Institute, London, UK

GCOS2016-P1-008

Cardiac complications after bone marrow transplantation: incidence of disease and associated risk factors

Presenting Author: Dr. Jose David Chuquin, Virginia Commonwealth University Medical Center, Richmond, VA, USA

GCOS2016-P1-009

Building a targeted approach to assessing risk of anthracycline induced cardiomyopathy

Presenting Author: Dr. Rachel Conyers, Children’s Cancer Center, The Royal Children’s Hospital, Melbourne, Victoria, Australia

GCOS2016-P1-010

The role of 2D-Transthoracic Echocardiography in patients with Multiple Myeloma

Presenting Author: Dr. Sorin Danciu, Advocate Illinois Masonic Medical Center, Chicago, IL, USA 

GCOS2016-P1-011

Cancer-related cardiac toxicities: Psychological correlates

Presenting Author: Dr. Susan Dent, The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada

GCOS2016-P1-012

Detection of apoptosis and relationship to ventricular function in patients with early stage breast cancer receiving anthracycline-based chemotherapy

Presenting Author: Dr. Susan Dent, The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada

GCOS2016-P1-013

Assessment of LVEF by CMR versus MUGA in Breast Cancer Patients Receiving Trastuzumab: A Blinded Prospective Observational Pilot Study

Presenting Author: Vinita Dhir, Division of Hematology/Oncology, St. Michael’s Hospital, Toronto, ON, Canada

GCOS2016-P1-014

Electrocardiographic Changes Associated with Ibrutinib Use

Presenting Author: Dr. Michael Fradley, Lee Moffitt Cancer Center and Research Institute, University of South Florida, Morsani College of Medicine, Tampa, FL, USA

GCOS2016-P1-015

“It’s not just the chemo” – a case of exertional dyspnoea in a Hodgkin survivor

Presenting Author: Dr. Arjun Ghosh, Department of Cardiology, Barts Heart Centre, St Bartholomew’s Hospital, Barts Health NHS Trust, West Smithfield, London, UK

GCOS2016-P1-016

An evaluation of cardiovascular and oncologic outcomes associated with interruption vs. continuation of adjuvant trastuzumab following the development of mild left ventricular dysfunction

Presenting Author: Jordan Gibson, Vancouver Fraser Medical Program, University of British Columbia, Vancouver, BC, Canada

GCOS2016-P1-017

Real world experience of screening for cardiotoxicity in a major UK cancer center – what can we learn?

Presenting Author: Dr. Dionisio Izquierdo, Cardio-Oncology Service, Barts Heart Centre, St. Bartholomew’s Hospital, Barts Health NHS Trust, London, UK 

GCOS2016-P1-018

Combined kinome and transcriptome profiling reveals broad and distinct activities of cardiosafe (erlotinib) and cardiotoxic (sunitinib, sorafenib) kinase inhibitors

Presenting Author: Dr. Brian Jensen, Division of Cardiology, University of North Carolina School of Medicine, Chapel Hill, NC, USA

GCOS2016-P1-019

Early myocardial strain changes during potentially cardiotoxic chemotherapy may occur due to reductions in LV end diastolic volume in addition to systolic dysfunction: The need to interpret LV strain with volumes

Presenting Author: Dr. Jennifer Jordan, Department of Internal Medicine, Section on Cardiovascular Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA

GCOS2016-P1-020

Elevated myocardial extracellular volume (ECV) occurs independently of LVEF declines in pediatric cancer survivors

Presenting Author:  Dr. Jennifer Jordan, Department of Internal Medicine, Section on Cardiovascular Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA

GCOS2016-P1-021

Cardio-protection from a single exercise session performed 24 hours prior to doxorubicin treatment in breast cancer patients

Presenting Author:  Amy Kirkham, University of Alberta, Edmonton, AB, Canada

GCOS2016-P1-022

Opportunities for Analytical and Cognitive Technology Innovation in Cardiac Oncology

Presenting Author:  Marianna Krive, Division of Cardiology, Advocate Lutheran General Hospital, Park Ridge, Illinois, USA

GCOS2016-P1-023

Anthracycline Cardiotoxicity in Patients with Acute Myeloid Leukemia Undergoing Intensive Therapies: A pilot study of the evaluation of current standards in cardiovascular risk assessment, monitoring, and management

Presenting Author: Dr. Stella Kyung, Division of Cardiology, Stony Brook University Hospital, Stony Brook, NY, USA

GCOS2016-P1-024

Changes in global longitudinal strain according to BRCA1/2 mutation status in patients with history of breast cancer treated with anthracyclines

Presenting Author: Dr. Bryan LeBude, Division of Cardiology, MedStar Heart and Vascular Institute, MedStar Washington Hospital Center, Washington, DC, USA

GCOS2016-P1-025

Exercise Right Heart Catheterization for Pulmonary Hypertension Identified on Screening Echocardiography in Adult Survivors of Childhood Cancer: A report from the St. Jude Lifetime Cohort

Presenting Author: Dr. Daniel Lenihan, Division of Cardiovascular Medicine, Vanderbilt University, Nashville, TN, USA

GCOS2016-P1-026

RADICAL PC: A Prospective Multicentre Study of Cardiovascular Disease in Men with Prostate Cancer

Presenting Author: Dr. Darryl Leong, The Population Health Research Institute, McMaster University and Hamilton Health Sciences, Toronto, ON, Canada

GCOS2016-P1-027

Adverse maternal cardiac and fetal outcomes in pregnant women with treated cancer

Presenting Author: Dr. Shiying Liu, Division of Cardiology, Department of Medicine, University Health Network, University of Toronto, Toronto, ON, Canada

GCOS2016-P1-028

Real-time optical mapping of acute mitochondrial dysfunction with chemotherapy agent doxorubicin in Langendorff-perfused rat hearts

Presenting Author: Dr. Alexander Lyon, Myocardiac Function, NHLI, Imperial College London, London, UK

GCOS2016-P1-029

Development of a Cardio-Oncology Service in the United Kingdom – a Report of 5 Year Experience

Presenting Author: Dr. Alexander Lyon, Myocardiac Function, NHLI, Imperial College London, London, UK

GCOS2016-P1-030

Hypoxic preconditioning protects adult cardiomyocytes from Doxorubicin-induced injury

Presenting Author:  Dr. Angshuman Maulik, Hatter Cardiovascular Institute, University College London, London, UK

GCOS2016-P1-031

Left ventricular end-diastolic volume mediated declines in ejection fraction after potentially cardiotoxic cancer treatment

Presenting Author: Dr. Giselle Melendez, Department of Internal Medicine, Section on Cardiovascular Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA

GCOS2016-P1-032

Effects of Proteasome Inhibition on Vascular Function

Presenting Author: Dr. Arvind Pandey, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA

GCOS2016-P1-033

Characteristics of cancer patients and survivors undergoing transcatheter aortic valve replacement

Presenting Author: Dr. Aarti Patel, University of South Florida, Department of Cardiovascular Sciences, Tampa, FL, USA

GCOS2016-P1-034

Clinical characteristics of patients with cancer and acute coronary syndrome

Presenting Author: Dr. Grzegorz Piotrowski, Cardiology Department, Nicolaus Copernicus Memorial Hospital, Lodz, Poland

GCOS2016-P1-035

Establishing the Type of Cardiac Amyloidosis: A Clinical Challenge

Presenting Author: Dr. Karen Riggins, Vanderbilt University Medical Center, Nashville, TN, USA

GCOS2016-P1-036

Pathological Correlates and Outcomes from Treatment of Cardiac Light Chain (AL) Amyloidosis

Presenting Author: Alexandra Ritts, Department of Internal Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA

GCOS2016-P1-037

Cardiac SAFEty of HER2 targeted therapy in patients with HER2 positive breast cancer and reduced left ventricular function: SAFE-HEaRT

Presenting Author: Arielle Schwartz, Georgetown University School of Medicine, Washington, DC, USA

GCOS2016-P1-038

Identifying the Incidence of Trastuzumab-Induced Cardiotoxicity at a “Real World” Tertiary Care Centre

Presenting Author: Grace Tang, Division of Medical Oncology, St. Michael’s Hospital, Toronto, ON, Canada

GCOS2016-P1-039

Feasibility of Optimal Echocardiographic Myocardial Strain Imaging for Cancer Therapy Monitoring: the Community Health Network Experience

Presenting Author: Dr. Rey Vivo, Community Heart and Vascular Hospital, Indianapolis, IN, USA

GCOS2016-P1-040

Early changes in biomarkers of nitrosative stress are associated with doxorubicin and trastuzumab-induced cardiac dysfunction in breast cancer patients

Presenting Author: Dr. Teresa Wang, Division of Cardiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA      

GCOS2016-P1-041

Relationship between three-dimensional myocardial strain and non-contrast tissue mapping by cardiac magnetic resonance imaging in patients receiving anthracycline-based chemotherapy

Presenting Author: Dr. James White, Department of Diagnostic Imaging, University of Calgary, Calgary, AB, Canada

GCOS2016-P1-042

Identifying research-practice gaps for mapping research priorities in response to clinical cardiotoxicity induced by targeted anticancer therapeutics

Presenting Author: Dr. Ping-Pin Zheng, Department of Pathology, Erasmus Medical Centre, Rotterdam, The Netherlands

GCOS2016-P1-043

Sex-dependent Alteration of Cytochrome P450 Expression by Acute Doxorubicin Cardiotoxicity

Presenting Author: Dr. Beshay Zordoky, Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA